381 related articles for article (PubMed ID: 22940233)
1. Can we reduce the dosage of biologics in spondyloarthritis?
Olivieri I; D'Angelo S; Padula A; Leccese P; Nigro A; Palazzi C
Autoimmun Rev; 2013 May; 12(7):691-3. PubMed ID: 22940233
[TBL] [Abstract][Full Text] [Related]
2. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Wang S; He Q; Shuai Z
Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Callhoff J; Sieper J; Weiß A; Zink A; Listing J
Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
[TBL] [Abstract][Full Text] [Related]
4. Biological therapies in the spondyloarthritides--the current state.
Braun J; Sieper J
Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
Braun J; Kiltz U; Heldmann F; Baraliakos X
Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
[TBL] [Abstract][Full Text] [Related]
7. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
8. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
9. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
[TBL] [Abstract][Full Text] [Related]
10. New evidence on the management of spondyloarthritis.
Sieper J; Poddubnyy D
Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489
[TBL] [Abstract][Full Text] [Related]
11. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.
Braun J; Baraliakos X; Heldmann F; Kiltz U
Expert Opin Investig Drugs; 2014 May; 23(5):647-59. PubMed ID: 24654630
[TBL] [Abstract][Full Text] [Related]
13. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
Poddubnyy D; Gensler LS
Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):807-18. PubMed ID: 25488786
[TBL] [Abstract][Full Text] [Related]
15. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
Michelsen B; Sexton J; Wierød A; Bakland G; Rødevand E; Krøll F; Kvien TK
Semin Arthritis Rheum; 2020 Feb; 50(1):12-16. PubMed ID: 31358361
[TBL] [Abstract][Full Text] [Related]
16. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
Malaviya AN; Kalyani A; Rawat R; Gogia SB
Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapies for spondyloarthritis: what is new?
Baraliakos X; Braun J
Curr Rheumatol Rep; 2012 Oct; 14(5):422-7. PubMed ID: 22855297
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.
Poddubnyy D; Rudwaleit M
Expert Opin Biol Ther; 2013 Nov; 13(11):1599-611. PubMed ID: 24074224
[TBL] [Abstract][Full Text] [Related]
19. Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment.
Paramarta JE; De Rycke L; Ambarus CA; Tak PP; Baeten D
Rheumatology (Oxford); 2013 Oct; 52(10):1873-8. PubMed ID: 23861532
[TBL] [Abstract][Full Text] [Related]
20. Tapering biologics in axial spondyloarthritis: A systematic literature review.
Saoussen M; Yasmine M; Lilia N; Alia F; Hiba B; Kawther BA; Ahmed L
Int Immunopharmacol; 2022 Nov; 112():109256. PubMed ID: 36150228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
